Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors
Abstract Somatostatin analogues have recently been used as therapeutic targets for metastatic or surgically unresectable gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), and associated somatostatin receptor (SSTR) expression has been well demonstrated in most GEP NETs, with the exception o...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-54599-4 |
| _version_ | 1797274619035516928 |
|---|---|
| author | Joo Young Kim Jisup Kim Yong-il Kim Dong-Hoon Yang Changhoon Yoo In Ja Park Baek-Yeol Ryoo Jin-Sook Ryu Seung-Mo Hong |
| author_facet | Joo Young Kim Jisup Kim Yong-il Kim Dong-Hoon Yang Changhoon Yoo In Ja Park Baek-Yeol Ryoo Jin-Sook Ryu Seung-Mo Hong |
| author_sort | Joo Young Kim |
| collection | DOAJ |
| description | Abstract Somatostatin analogues have recently been used as therapeutic targets for metastatic or surgically unresectable gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), and associated somatostatin receptor (SSTR) expression has been well demonstrated in most GEP NETs, with the exception of rectal NETs. SSTR2 immunohistochemical expressions were evaluated in 350 surgically or endoscopically resected rectal NETs and compared to clinicopathologic factors. SSTR2 expression was observed in 234 (66.9%) rectal NET cases and associated tumors with smaller size (p = 0.001), low pT classification (p = 0.030), low AJCC tumor stage (p = 0.012), and absence of chromogranin expression (p = 0.009). Patients with rectal NET and SSTR2 expression had significantly better overall survival than those without SSTR2 expression both by univariable (p = 0.006) and multivariable (p = 0.014) analyses. In summary, approximately two-thirds of rectal NETs expressed SSTR2. SSTR2 expression was significantly associated with favorable behavior and good overall survival in patients with rectal NETs. Furthermore, SSTR2 expression can be used as prognostic factors. When metastatic disease occurs, SSTR2 expression can be used a possible target for somatostatin analogues. |
| first_indexed | 2024-03-07T15:01:51Z |
| format | Article |
| id | doaj.art-e4e73fe04ec64937b6d26c6991a43ad7 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-07T15:01:51Z |
| publishDate | 2024-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-e4e73fe04ec64937b6d26c6991a43ad72024-03-05T19:09:02ZengNature PortfolioScientific Reports2045-23222024-02-011411810.1038/s41598-024-54599-4Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumorsJoo Young Kim0Jisup Kim1Yong-il Kim2Dong-Hoon Yang3Changhoon Yoo4In Ja Park5Baek-Yeol Ryoo6Jin-Sook Ryu7Seung-Mo Hong8Department of Pathology, Chung-Ang University Hospital, College of Medicine, Chung-Ang UniversityDepartment of Pathology, Gil Medical Center, Gachon University College of MedicineDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of MedicineDepartments of Gastroenterology, Asan Medical Center, University of Ulsan College of MedicineDepartments of Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartments of Colon and Rectal Surgery, Asan Medical Center, University of Ulsan College of MedicineDepartments of Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of MedicineDepartment of Pathology, Asan Medical Center, University of Ulsan College of MedicineAbstract Somatostatin analogues have recently been used as therapeutic targets for metastatic or surgically unresectable gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), and associated somatostatin receptor (SSTR) expression has been well demonstrated in most GEP NETs, with the exception of rectal NETs. SSTR2 immunohistochemical expressions were evaluated in 350 surgically or endoscopically resected rectal NETs and compared to clinicopathologic factors. SSTR2 expression was observed in 234 (66.9%) rectal NET cases and associated tumors with smaller size (p = 0.001), low pT classification (p = 0.030), low AJCC tumor stage (p = 0.012), and absence of chromogranin expression (p = 0.009). Patients with rectal NET and SSTR2 expression had significantly better overall survival than those without SSTR2 expression both by univariable (p = 0.006) and multivariable (p = 0.014) analyses. In summary, approximately two-thirds of rectal NETs expressed SSTR2. SSTR2 expression was significantly associated with favorable behavior and good overall survival in patients with rectal NETs. Furthermore, SSTR2 expression can be used as prognostic factors. When metastatic disease occurs, SSTR2 expression can be used a possible target for somatostatin analogues.https://doi.org/10.1038/s41598-024-54599-4SomatostatinReceptor 2RectumNeuroendocrine tumorPrognosis |
| spellingShingle | Joo Young Kim Jisup Kim Yong-il Kim Dong-Hoon Yang Changhoon Yoo In Ja Park Baek-Yeol Ryoo Jin-Sook Ryu Seung-Mo Hong Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors Scientific Reports Somatostatin Receptor 2 Rectum Neuroendocrine tumor Prognosis |
| title | Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors |
| title_full | Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors |
| title_fullStr | Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors |
| title_full_unstemmed | Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors |
| title_short | Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors |
| title_sort | somatostatin receptor 2 sstr2 expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors |
| topic | Somatostatin Receptor 2 Rectum Neuroendocrine tumor Prognosis |
| url | https://doi.org/10.1038/s41598-024-54599-4 |
| work_keys_str_mv | AT jooyoungkim somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT jisupkim somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT yongilkim somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT donghoonyang somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT changhoonyoo somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT injapark somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT baekyeolryoo somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT jinsookryu somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors AT seungmohong somatostatinreceptor2sstr2expressionisassociatedwithbetterclinicaloutcomeandprognosisinrectalneuroendocrinetumors |